PUBLIC COMPANY
saveFusion Pharmaceuticals Inc
updated 2mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 12Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- phase2FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- phase2Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
- phase1A Phase 1 Study of [225Ac]-FPI-1434 Injection
- phase2A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that